Comerica Bank
ARQT icon

Comerica Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Comerica Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.74K Sell
95
-40
-30% -$1.02K ﹤0.01% 3491
2025
Q3 		$2.54K Sell
135
-1,507
-92% -$23.8K ﹤0.01% 3498
2025
Q2 		$23K Buy
1,642
+1,141
+228% +$16K ﹤0.01% 3012
2025
Q1 		$7.83K Buy
501
+26
+5% +$366 ﹤0.01% 3230
2024
Q4 		$6.62K Hold
475
– – ﹤0.01% 3253
2024
Q3 		$4.42K Buy
475
+318
+203% +$3.14K ﹤0.01% 3364
2024
Q2 		$1.46K Sell
157
-182
-54% -$1.65K ﹤0.01% 3542
2024
Q1 		$3.36K Buy
339
+249
+277% +$1.86K ﹤0.01% 3424
2023
Q4 		$291 Hold
90
– – ﹤0.01% 3690
2023
Q3 		$478 Buy
+90
New +$765 ﹤0.01% 3717

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return